Comparative Study
doi: 10.1016/S0140-6736(03)14294-8.
Candesartan and heart failure: the allure of CHARM
Affiliations
- PMID: 13678864
- DOI: 10.1016/S0140-6736(03)14294-8
Item in Clipboard
Comparative Study
Candesartan and heart failure: the allure of CHARM
Lancet.
.
No abstract available
Comment in
-
The CHARM programme.Lancet. 2003 Nov 15;362(9396):1678; author reply 1678-9. doi: 10.1016/S0140-6736(03)14813-1. Lancet. 2003. PMID: 14630459 No abstract available.
Comment on
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.Lancet. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1. Lancet. 2003. PMID: 13678868 Clinical Trial.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5. Lancet. 2003. PMID: 13678870 Clinical Trial.
-
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.Lancet. 2003 Sep 6;362(9386):777-81. doi: 10.1016/S0140-6736(03)14285-7. Lancet. 2003. PMID: 13678871 Clinical Trial.
Similar articles
-
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.J Hypertens Suppl. 2006 Mar;24(1):S3-7. doi: 10.1097/01.hjh.0000220400.08128.fa. J Hypertens Suppl. 2006. PMID: 16601570 Clinical Trial.
-
[CHARM study--new strategy for the treatment of heart failure].Nihon Rinsho. 2004 May;62(5):995-1002. Nihon Rinsho. 2004. PMID: 15148833 Review. Japanese.
-
Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.J Hypertens Suppl. 2006 Mar;24(1):S9-13. doi: 10.1097/01.hjh.0000220401.15751.3f. J Hypertens Suppl. 2006. PMID: 16601580 Review.
-
The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.Cardiovasc J S Afr. 2004 Jan-Feb;15(1):42-3. Cardiovasc J S Afr. 2004. PMID: 15095753 No abstract available.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
Cited by
-
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Circulation. 2015 May 12;131(19):e435-70. doi: 10.1161/CIR.0000000000000207. Epub 2015 Mar 31. Circulation. 2015. PMID: 25829340 Free PMC article. No abstract available.
-
Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences.Neth Heart J. 2006 Nov;14(11):381-387. Neth Heart J. 2006. PMID: 25696573 Free PMC article.
-
Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy.Vasc Health Risk Manag. 2008;4(1):223-34. doi: 10.2147/vhrm.2008.04.01.223. Vasc Health Risk Manag. 2008. PMID: 18629370 Free PMC article.
-
Hypertension in the elderly: a Japanese perspective.Drugs Aging. 2005;22(4):297-314. doi: 10.2165/00002512-200522040-00003. Drugs Aging. 2005. PMID: 15839719 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
